IGHE and asthma: In the randomized, double- blind, placebo-controlled study on the effects of humanized monoclonal anti-IgE antibody, omalizumab on NP and comorbid asthma (38), omalizumab reduced the total nasal endoscopic polyp score and demonstrated significant benefits for nasal and respiratory symptoms, such as nasal congestion, anterior rhinorrhea, loss of smelling sense, wheezing, and dyspnea.